American Journal of Kidney Diseases
LightNews LightNews
banner
ajkd.bsky.social
American Journal of Kidney Diseases
@ajkd.bsky.social
3K followers 630 following 1.2K posts
AJKD, official journal of @kidney.org, is the leading source of information devoted to clinical nephrology research and practice. AJKD.org | AJKDblog.org | Organizer of #NephMadness @nephmadness.bsky.social
Posts Replies Media Videos
ajkd.bsky.social
Perspective by Yuvaram N.V. Reddy, Laura Ellen Ashcraft , and Mallika L. Mendu:

How to Leverage Implementation Science to Achieve Equity in Nephrology Care Delivery

bit.ly/Reddy25Pers
November 11, 2025 at 11:00 AM
ajkd.bsky.social
NEW ON #AJKDBlog:

This year AJKD inducted seven remarkable reviewers into the AJKD Reviewer Hall of Fame. The editors thank and congratulate these reviewers, all of whom shared why they participate in the peer review process:

bit.ly/47y3R0o
November 10, 2025 at 11:00 PM
ajkd.bsky.social
Corticosteroid, Parathyroid Hormone, and Body Composition Associations With Bone Density and Structure Following Kidney Transplantation

bit.ly/47wHN6h #OpenAccess
November 10, 2025 at 5:02 PM
ajkd.bsky.social
Core Curriculum by Craig E. Gordon et al:

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025
bit.ly/465twwK (FREE)
The Mayo Imaging Classification of ADPKD description (left panel) and imaging examples (right panel) with examples (right panel) of (a, b) subclass 1A and 1E, (c-f) subclass 2A, and (g, h) subclass 2B. Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; TKV, total kidney volume. Reproduced with permission of the copyright holder (Kidney Disease: Improving Global Outcomes) from Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group. KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(suppl 2S):S1-S239. doi:10.1016/j.kint.2024.07.009
November 10, 2025 at 11:01 AM
ajkd.bsky.social
EDITORIAL: Choices Matter: Expanding the Quality of Shared Decision-Making for Older Adults With Advanced CKD

bit.ly/4qPgECY (FREE)
November 9, 2025 at 11:01 PM
ajkd.bsky.social
2025 AJKD Editors' Choice Award winning article: Continuous Kidney Replacement Therapy and Survival in Children and Young Adults: Findings From the Multinational WE-ROCK Collaborative

bit.ly/4ovaAyd

#VisualAbstract
November 9, 2025 at 5:02 PM
ajkd.bsky.social
Cellular variant of focal segmental glomerulosclerosis, with endocapillary hypercellularity with foam cells and mononuclear cells (top; Jones silver stain)"

bit.ly/4nNJdy2 (FREE)

#renalpath #FSGS
November 9, 2025 at 11:00 AM
ajkd.bsky.social
Primary Care Use and Clinical Outcomes Among Patients Initiating Hemodialysis

bit.ly/46baANd #OpenAccess

#VisualAbstract
November 8, 2025 at 11:01 PM
ajkd.bsky.social
NEW on #AJKDBlog: 2025 Editors’ Choice Award

The editors are delighted to recognize 8 articles that have been selected to receive the 2025 Editors’ Choice Award. These articles will be freely available at AJKD.org until January 31, 2026.

bit.ly/480B6cM
November 8, 2025 at 5:00 PM
ajkd.bsky.social
A 40-year-old male patient on maintenance hemodialysis for 2 years presented to the hospital with sudden-onset left flank pain and gross hematuria. What is the differential diagnosis of gross hematuria in a hemodialysis patient?

bit.ly/4p2R4sI (FREE)
November 8, 2025 at 11:00 AM
ajkd.bsky.social
Mini Review by Kristen L. Nowak and Michel Chonchol:

Targeting Inflammation in CKD

bit.ly/46TMzsY (FREE)
Inflammatory Signaling and Potential Therapeutic Targets in CKD. Sterile inflammation triggered by innate immune system activation is a key driver of both chronic kidney disease (CKD) and associated atherosclerosis and cardiovascular disease (CVD), in part via activation of the NLRP3 inflammasome. Recent and ongoing clinical trials are testing therapeutics targeting the NLRP3 inflammasome, interleukin-1 (IL-1) and its receptor (IL-1R), interleukin-6 (IL-6) and its receptor (IL6R), as represented in this schematic.
November 7, 2025 at 11:00 PM
ajkd.bsky.social
In celebration of #KidneyWk, the entire November issue is FREE to access until November 30, 2025!

Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/3X1XpZj
November 7, 2025 at 9:57 PM
ajkd.bsky.social
Development and Evaluation of Machine Learning Models to Predict the Risk of Major Cardiac Events and Death for People With Kidney Failure Having Non-Cardiac Surgery

bit.ly/3W3ifa7
Calibration plots for parsimonious random forest model across cohorts Parsimonious model includes selected features namely age, sex, surgery type (vascular, more than one, peritoneal dialysis, arteriovenous fistula, musculoskeletal, low-risk surgeries), surgery setting (emergency inpatient and outpatient), kidney failure type (hemodialysis), comorbidities (history of myocardial infarction, dementia, chronic pulmonary disease, liver disease, peripheral vascular disease, cancer), albumin and hemoglobin values. Each dot represents decile grouping based on predicted risk.
November 7, 2025 at 5:02 PM
ajkd.bsky.social
Mini-Review by Aleksandra Kukla, Ricardo Cohen, and Allon Friedman:

Metabolic Bariatric Surgery in Kidney Transplant Candidates

bit.ly/3Vzeauk
Suggested weight loss treatment pathways to achieve eligibility for kidney transplantation for patients with advanced kidney disease. aGLP1/GIP RA should be considered in all kidney transplant candidates as either a bridge to MBS, an alternative to MBS, or to enhance the weight loss effect of MBS. bNo rigid upper age limit for bariatric surgery. Frailty, not chronological age, should guide decision making. Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; GIP, glucose-dependent insulinotropic polypeptide; GLP1 RA, glucagon-like peptide-1 receptor agonist; MBS, metabolic bariatric surgery; T1D, type 1 diabetes; T2D, type 2 diabetes; SPK, simultaneous pancreas and kidney transplant.
November 7, 2025 at 11:00 AM
ajkd.bsky.social
Intronic and Coding Genetic Variants in Autosomal Recessive Polycystic Kidney Disease Among Israeli Bedouins of Arabian Peninsula Ancestry

bit.ly/Agam25OI

#ARPKD #VisualAbstract
November 6, 2025 at 11:00 PM
ajkd.bsky.social
Interpreting Metabolomics and Proteomics in Kidney Disease: A Practical Guide by Insa M. Schmidt and Eugene P. Rhee

bit.ly/4ooxkQ6
November 6, 2025 at 5:02 PM
ajkd.bsky.social
NEW on #AJKDBlog: 2025 Editors’ Choice Award

The editors are delighted to recognize 8 articles that have been selected to receive the 2025 Editors’ Choice Award. These articles will be freely available at AJKD.org until January 31, 2026.

bit.ly/480B6cM
November 6, 2025 at 11:02 AM
ajkd.bsky.social
Health Outcome Preferences and Trade-Offs Among Older Adults With Advanced CKD: A Discrete Choice Experiment

bit.ly/Schoot25OI #OpenAccess

#CKD #VisualAbstract
November 5, 2025 at 11:00 PM
ajkd.bsky.social
Evaluating Intervention Rates for Dysfunctional Arteriovenous Fistulas: Post-hoc Analysis of the IN.PACT AV Access Trial

bit.ly/3X8xwab

#VisualAbstract
November 5, 2025 at 5:04 PM
ajkd.bsky.social
EDITORIAL by Katherine A. Barraclough and Jane Waugh:

Reducing the Environmental Footprint of Hemodialysis: The Case for Centralized Acid Delivery

bit.ly/4oRMMV2 (FREE)
November 5, 2025 at 11:01 AM
ajkd.bsky.social
In the Literature by Stephanie M. Hu:

Understanding Estimated GFR

bit.ly/3JdrUIH (FREE)
November 4, 2025 at 11:01 PM
ajkd.bsky.social
Living Kidney Donors’ Residential Neighborhoods: Driver or Barrier of Postdonation Follow-Up?

bit.ly/3X7hi13 (FREE)
November 4, 2025 at 5:05 PM
ajkd.bsky.social
Remembering and Honoring James Kaufman, MD

Dr. James Kaufman who served as Associate Editor of the American Journal of Kidney Diseases for 19 years (2006-2025).

bit.ly/42boJHq
November 4, 2025 at 11:01 AM
ajkd.bsky.social
The November 2025 issue is available now! Check out the plain-language summaries on what inspired each study, the basic approach taken, what was learned, and why it matters:

bit.ly/3X1XpZj
November 3, 2025 at 11:00 PM
ajkd.bsky.social
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY

bit.ly/3WA9uoy (OPEN ACCESS)
Effect of empagliflozin versus placebo on study average concentration of urine biomarkers (indexed to urine creatinine). The MMRM model was adjusted for the prognostic variables specified in the minimized randomization algorithm (i.e., age, sex, prior diabetes, eGFR, uACR, and trial site region) in the same categories used in the minimization process, initial freezer storage temperature (-20°C versus below -20°C) and baseline log2-transformed urine biomarker-creatinine ratio. A weighted average of 2- and 18- month values proportional to the amount of time between visits was used to estimate the study average log2-transformed urine biomarker-to-creatinine ratio in each arm. Absolute values indicate geometric mean (approximate SE) creatinine-indexed urine biomarker concentration in the units specified. The size of the boxes represents the amount of information estimated.
November 3, 2025 at 5:03 PM